Genescient Receives Additional Angel Funding
Irvine, CA, December 17, 2009 — Genescient Corporation, a California genomic-health biotechnology company, received $500,000 in new angel investment, to help commercialize the company’s technology and to fund further research.
The investment was made by private investors with an interest in the rapidly growing field of nutrigenomics, based on the science of epigenetics and its promise of healthy life extension. A spokesman for the investors, Douglas Arends, stated: “We are especially interested in the genomics work Genescient has completed to identify human genes of aging. This knowledge, gained from decades of selective breeding of model animals for longevity, will to lead to the production of nutrigenomic compounds in 2010. The plan is to build on this work and, in later years, to develop drugs aimed at treating age-associated chronic diseases and provide patients with healthy life extension. We are predicting that Genescient will become a leader in its field, with the knowledge that it now has providing it with a significant head start”.”
Damian Crowe, CEO of Genescient, said “The angel investment enables Genescient to further exploit the treasure trove of human genomic targets it currently owns, the goal being to offer better genomic information and superior health-enhancing products to its clients.”
About Genescient Corporation:
Genescient Corporation is a California evolutionary genomics company. Its technology is based on the genomics of model organisms selectively bred for health and longevity over 30 years. This genomic information is combined with whole-genome data, and massive clinical databases to identify, screen and develop benign therapeutic substances for the treatment of the chronic aging-associated diseases including cardiovascular disease, Type II diabetes, and neurodegenerative diseases. Genescient will also provide its clients with genomic information services that address the genes responsible for the complex genomic trait “rate of aging”.
Damian Crowe, CEO
+1 949-333-0058 x3305